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Introduction 
Whether research results should be returned to par-
ticipants has been an ongoing debate in the research 
and bioethics communities for years. The debate has 
become more complicated as advances in technology 
permit the discovery through genomic sequencing of 
a growing number of findings that may or may not 
have clinical relevance for research participants. As 
part of the larger conversation regarding whether and 
under what circumstances research results should be 
returned to participants, research conducted using 
residual newborn screening dried blood samples 
(DBS) deserves special consideration due to the nature 
of newborn screening, the recent controversy regard-
ing the retention and use of DBS, and the impact of 
this controversy on state newborn screening programs.
Currently, there is a disconnect between the poten-
tial benefits — both to the population at large and to 
individual infants and their families — of research 
that could be conducted using DBS and the practi-
cal capabilities of state newborn screening programs. 
Although as a society, we are on the cusp of being able 
to bring about significant improvements in health as 
a result of research conducted in the newborn period, 
budget constraints, political exigencies, and concerns 
about the potential negative impact on the primary 
public health mission of newborn screening may limit 
the ability and/or willingness of state newborn screen-
ing programs to support the secondary research use of 
DBS and the return of results to research participants. 
The full value of research using DBS has not been 
realized previously for a variety of reasons, including 
the fact that population-based DBS studies can only 
be conducted in a limited number of states.1 Over time, 
however, if state policies are amended, DBS could be 
utilized to develop a population-wide genomic data-
base. Genetic information linked with clinical infor-
mation over the course of a person’s lifetime could 
provide unprecedented opportunities to learn about 
human health and disease from the early stages of life.2 
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The potential benefits of research conducted with 
DBS can only be achieved if there is broad support 
from the newborn screening community and buy-in 
from the general public. Returning research results in 
some circumstances is one potential way to enhance 
public buy-in. If the full value of research conducted 
using DBS is to be achieved, results of research con-
ducted using DBS should be returned to infants’ 
families under some circumstances. This article will 
explore the circumstances under which it may be ben-
eficial to research participants, state newborn screen-
ing programs, and the research enterprise to return a 
subset of research results to parents. Returning some 
results of research conducted using DBS will require 
significant changes to the newborn screening program 




The purpose of newborn screening is to identify infants 
with certain serious medical conditions and allow for 
early interventions to avoid or ameliorate clinical 
symptoms and prevent disability or death. Newborn 
screening is mandated by state law in the District of 
Columbia and all 50 states, except Wyoming.3 Shortly 
after birth, whether born at home or in a hospital, a 
newborn’s heel is pricked, and several drops of blood 
are placed on filter paper that is sent to the state new-
born screening laboratory when the blood has dried. It 
has been estimated that 1 in 300 newborns has one of 
the newborn screening conditions, and an estimated 
12,500 children with metabolic, endocrine, hemato-
logic, or functional disorders are identified through 
newborn screening each year.4 After diagnostic con-
firmation, these infants are referred for treatment and 
long-term follow-up. 
B. Secondary Uses of Residual Newborn Screening DBS
When the heel stick is performed, more blood is col-
lected from each newborn than is required to perform 
newborn screening. This extra blood is collected so 
that the blood can be re-evaluated if warranted by the 
initial screen results and to ensure that there is suf-
ficient blood to perform the initial screening. As a 
result, when newborn screening has been completed, 
residual DBS remain. 
DBS have a broad range of potential secondary uses, 
including program quality assurance, test validation, 
and the development of new newborn screening tests. 
For example, DBS were used to develop a screening 
test for Severe Combined Immunodeficiency Disorder 
(SCID), a condition that was added in 2011 to the list 
of core conditions recommended for inclusion in state 
newborn screening panels by the Secretary’s Advisory 
Committee on Heritable Disorders in Newborns and 
Children.5 DBS also have been used to evaluate the 
feasibility of using new technology, such as next gen-
eration sequencing, to improve upon current newborn 
screening methods.6 
DBS also may be used for research unrelated to new-
born screening. DBS are whole blood samples and con-
tain a wide range of biomarkers, including DNA, RNA, 
and proteins.7 DBS have been used to explore the possi-
ble etiology of a wide variety of conditions, from child-
hood leukemia8 to autism,9 and they have been used 
to provide evidence of exposure to infectious diseases10 
and environmental toxins. For example, in the “Mer-
cury in Newborns from the Lake Superior Basin” study, 
DBS from three states were evaluated to assess prena-
tal mercury exposure because even small amounts of 
mercury can harm the developing brain and nervous 
system. These results were used to improve outreach 
to pregnant mothers and their health care providers to 
promote eating types of fish low in mercury.11
Since newborn screening is conducted on almost all 
of the babies born in the United States, DBS provide a 
nearly complete representation of the U.S. population. 
In the future, information derived from DBS could be 
integrated with other public health surveillance data, 
such as environmental health tracking programs or the 
Behavioral Risk Factor Surveillance System (BRFSS) 
This article will explore the circumstances under which it may be  
beneficial to research participants, state newborn screening programs,  
and the research enterprise to return a subset of research results to parents. 
Returning some results of research conducted using DBS will require 
significant changes to the newborn screening program infrastructure.  
We offer a starting point for discussion of these issues.
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maintained by the Centers for Disease Control and 
Prevention,12 to provide a rich resource for research. 
In addition, the National Institutes of Health (NIH) 
have made a significant investment in newborn screen-
ing research. Under the Genomic Sequencing and 
Newborn Screening Disorders program, the Eunice 
Kennedy Shriver National Institute of Child Health 
and Human Development (NICHD) and the National 
Human Genome Research Institute (NHGRI) have 
jointly funded pilot projects with awards of $5 million 
each to four grantees to assess whether “sequencing of 
newborns’ genomes provides useful medical informa-
tion beyond what current newborn screening already 
provides.”13 In addition, the American College of Med-
ical Genetics and Genomics (ACMG) was awarded 
a 5-year, $12.5 million extension of its contract by 
NICHD for the Newborn Screening Translational 
Research Network (NBSTRN) Coordinating Center to 
develop an infrastructure to support newborn screen-
ing reearch.14 One of the resources developed by the 
NBSTRN is a Virtual Repository of Dried Blood Spots, 
an open-source web-based tool that enables research-
ers to search over two million DBS that are available 
to researchers in participating states.15 The full value 
of these resources can only be realized if there is broad 
participation in the research. Returning results of the 
research in some form to parents may be one way to 
encourage participation. 
II. The Retention and Use of DBS
A. Litigation Regarding the Secondary Use of DBS 
The public health benefit of newborn screening can be 
expanded by using residual DBS for research, but the 
retention and secondary use of DBS have been contro-
versial in some states. It is important to understand 
the context of this controversy when considering the 
implications of returning or not returning results of 
research conducted with DBS. 
The public controversy surrounding the retention 
and use of DBS has focused on whether explicit paren-
tal permission should be required. Until recently, 
informed consent was not required by federal law 
to release DBS for research because research con-
ducted with de-identified DBS was not considered 
human subjects research under federal human sub-
jects research guidelines. Nevertheless, the retention 
of DBS without parental permission led to a firestorm 
of negative media attention and garnered incendiary 
headlines such as, “The Government Has Your Baby’s 
DNA!”16 and “Your Child’s DNA: Who Has It?”17 
Concerns of privacy advocates and some parents 
about the retention and use of DBS without explicit 
consent resulted in lawsuits against the state health 
departments in Texas,18 Minnesota,19 and Indiana.20 
As a result of the litigation in Texas and Minnesota, 
millions of DBS were destroyed, and parental consent 
now is required to release DBS for secondary research 
in both states. The litigation in Indiana is ongoing at 
the time of this writing. 
 The controversy generated by these lawsuits has led 
to concerns that state policies regarding the retention 
and use of residual DBS may have a negative impact 
on the primary public health mission of newborn 
screening. The fear is that parental concerns regard-
ing the possible research use of their children’s DBS 
will cause parents to refuse newborn screening alto-
gether. An editorial in Nature highlighted these con-
cerns by stating that “to be unclear about how new-
born blood is collected and used is the fastest route 
to turn the public against sampling of newborns for 
any purpose — including screening programs.”21 The 
perceived lack of transparency by state health depart-
ments that have not sought parental permission to 
release de-identified DBS for secondary research may 
undermine public trust in state newborn screening 
programs and the research enterprise. For this reason, 
consideration of any policies related to the secondary 
use of DBS, including whether and under what cir-
cumstances results of research conducted using DBS 
should be returned, must involve consideration of the 
impact of these policies and practices on the operation 
of state newborn screening programs. 
B. Federal Legislation Regarding  
Secondary Research Use of DBS
In the past, research conducted using de-identified 
DBS was not considered human subjects research 
under federal human subjects research guidelines, 
and parental informed consent was not required by 
federal law to release de-identified DBS for biomedical 
research.22 The Newborn Screening Saves Lives Reau-
thorization Act of 2014 changed these requirements 
by defining federally-funded research conducted using 
DBS as research on human subjects and limiting the 
federal provisions that permit Institutional Review 
Boards (IRBs) to modify or waive the requirement to 
obtain informed consent for research.23 
At the time of this writing, federal regulations to 
implement the legislation have not been promulgated, 
and the impact of the legislation on research con-
ducted using DBS is unclear, particularly with respect 
to whether informed consent will be required for all 
research conducted using DBS. As discussed above, 
a wide variety of activities can be conducted with 
DBS, and it is unclear how the term “research” will be 
defined in this context. For example, are pilot studies 
considered research that will require informed con-
sent? Another area that needs clarification is whether 
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blanket consent for research conducted with DBS will 
be sufficient. 
Given the potential policy and programmatic bar-
riers to adequately obtaining informed consent from 
parents for the research use of DBS, the Newborn 
Screening Saves Lives Reauthorization Act of 2014 
may significantly limit the use of DBS in biomedical 
research. When the legislation was enacted, federal 
law did not require parental consent to use de-iden-
tified DBS for research. Few states had mechanisms 
in place to solicit consent, and in those states, blanket 
consent for the future research use of DBS is requested 
rather than seeking specific consent for individual 
research studies. 
One state that has a mechanism in place to seek 
blanket consent for the future use of DBS is Michi-
gan. Michigan state law authorizes the retention of 
DBS.24 All DBS are stored in the Michigan BioTrust 
for Health, a biobank created to make DBS more use-
ful for medical and public health research, but paren-
tal consent is required to release DBS collected after 
April 30, 2010, for secondary research.25 Blanket 
parental consent for health research is requested at 
the time newborn screening testing is performed.
Massachusetts is the only state to our knowledge 
with a mechanism to request consent from parents of 
every baby born in the state to participate in a specific 
study — in this case, optional screening in a state-run 
pilot study.26 It is important to note that in Massachu-
setts, blanket consent for future research using DBS is 
not requested. 
A requirement to obtain informed consent to use 
DBS for federally-funded research may have implica-
tions for whether research results could or should be 
returned to individual participants. Requirements to 
obtain consent suggest that research participants can 
be identified and may indicate that participants have 
an expectation that results will be returned. 
In the past, when de-identified DBS were used for 
research, in many cases, the DBS were anonymized 
and did not retain any link to identifying informa-
tion, effectively removing the possibility of returning 
results to research participants. However, if consent is 
obtained to release DBS for secondary research, DBS 
could have identifying information stripped but retain 
a link to identifying information kept by the state new-
born screening program. In this way, the researcher 
could not easily ascertain the identity of the individual 
from whom the sample was obtained, but the state 
would have the information if necessary for the future 
re-identification of the child. The Michigan BioTrust 
has adopted this type of approach. The DBS stored in 
the BioTrust are double-coded, and only the Michigan 
Department of Community Health holds codes that 
identify to whom individual samples belong.27 The 
intent of the double-coding is to protect the privacy of 
newborns and facilitate the return of research results 
that might impact the health of the child. 
An alternative approach to releasing de-identified 
but linked samples would be to seek parental consent 
to release identifying information at the same time that 
parental consent is sought to release DBS for research. 
In this scenario, it would be possible to recontact fam-
ilies to provide them with research results. 
When parental consent has been sought to release 
DBS for secondary research, parents may have a 
desire or expectation that research results with poten-
tial importance for the health of their children will be 
returned to them. Whether parents expect research 
results to be returned to them is an empirical ques-
tion, but members of the public place high value on 
having research results returned. In 2011, 3,855 mem-
bers of the general public were surveyed to evaluate 
public opinions about the policies and practices rel-
evant to the retention and use of DBS for biomedical 
research. The survey addressed the potential tradeoff 
between removing identifiers from samples and the 
return of research results. Participants were informed 
that removing identifiers would increase privacy 
protections, but that if identifying information was 
retained with the DBS, important results about an 
infant’s health could be returned to the infant’s par-
ents. Sixty-four percent of participants responded 
that allowing the return of results to parents was more 
important than providing greater privacy protec-
tions.28 It should be noted that this question addressed 
the return of research results that may be important 
to the health of a child, not the return of all research 
results. If a research protocol that uses DBS requires 
informed consent but does not involve returning 
research results to participants’ parents, it is crucial 
that parents be informed that research results will not 
be returned to them so that their understanding of 
what to expect from their children’s participation in 
the research will be clear.
III. Is There a Legal Duty to Return Results 
from Research Conducted Using DBS?
A. State Law on Return of Results from Research 
Conducted Using DBS 
Currently, the laws of only three states specifically 
address the return of results from research con-
ducted using DBS. However, the return of results 
from research using DBS currently is not required by 
law in any state. In Massachusetts, the New England 
Newborn Screening Program allows parents to par-
ticipate in pilot studies of new tests. The Massachu-
setts Department of Health Regulations define the 
genomic research results to a participant’s family • fall 2015 563
Huckaby Lewis and Goldenberg 
pilot studies as “statewide testing and related screen-
ing activities offered through a research protocol with 
informed consent process approved by the Depart-
ment’s Institutional Review Board.”29 State regula-
tions require that the “pilot studies provide for the 
maintenance of specimen identifiers, allowing study 
results to be linked to, and reported for, specific indi-
viduals.”30 These regulations do not require that pilot 
study results be returned to infant’s parents, but in 
practice, the results of the pilot studies are reported 
with routine newborn screening results to the infants’ 
physicians.31 
The DBS stored in the Michigan BioTrust for Health 
are double-coded in order to enable re-identification 
of individual infants if necessary. The BioTrust poli-
cies do not contain guidance regarding the circum-
stances under which research results could or should 
be returned to infants’ families, and Michigan state 
law does not require that research results be returned 
to research participants. 
South Carolina law permits the Department of 
Health to return results of research conducted with 
DBS that may be important for the health of the 
child.32 However, the return of research results is not 
required, and no guidance is provided regarding the 
circumstances in which return of research results is 
appropriate. 
B. Newborn Screening Litigation Regarding the 
Return of Research Results
A Lexis/Nexis search of federal and state cases con-
ducted in February 2015 using the terms “newborn,” 
“screening,” “research,” and “results” generated 127 
cases. Two cases involved allegations related to a fail-
ure to return results of research conducted in the new-
born period. The remaining 125 cases did not involve 
failure to return research results. In Ande v. Fost, the 
plaintiffs were two parents whose newborn partici-
pated in a research study to “test for the presence of 
factors indicative of cystic fibrosis.”33 The study was 
conducted prior to the inclusion of cystic fibrosis (CF) 
on state newborn screening panels. In one arm of the 
study, parents were told if their child screened posi-
tive for CF and a “nutritional plan was made available 
to them immediately.”34 Parents of infants in the other 
arm were placed in a blinded control group and were 
not told if their child screened positive for CF. The 
plaintiffs’ child who participated in the study screened 
positive for CF, but these results were not given to the 
parents prior to her diagnosis with CF. 
The plaintiffs sued the investigators, the hospital 
where the infant was born, and the Wisconsin Depart-
ment of Health and Social Services. All claims except 
the allegation of medical malpractice were dismissed 
for procedural reasons. The circuit court concluded 
that the medical malpractice claim could not proceed 
because no physician-patient relationship between the 
plaintiffs and any of the defendants had been estab-
lished. The Wisconsin Court of Appeals affirmed the 
lower court’s decision.35 The results of this case might 
have been different if any of the researchers had been 
involved in the clinical care of the Andes’ child. 
In Dinkins v. Hutzel Hospital,36 the plaintiff was a 
mother who sued on behalf of the estate of her deceased 
daughter. The plaintiff gave birth to her daughter, 
Stephanie, at Huntzel Hospital in 1986, prior to the 
widespread adoption of sickle cell anemia screening 
as part of state newborn screening programs. At the 
time, the hospital cooperated “with an organization 
implementing a pilot program to screen for sickle cell 
disease, the Sickle Cell Detection and Information 
Program”37 (the Sickle Cell Program).
The Sickle Cell Program had routine procedures 
in place to notify families and physicians of any new-
born who tested positive for sickle cell disease, but 
the Sickle Cell Program failed to notify anyone that 
Stephanie had tested positive. She died when she was 
three years old after becoming sick with flu-like symp-
toms and being treated in an emergency room for a 
viral infection when in fact she was suffering from a 
sickle cell crisis.
Her mother sued Hutzel Hospital where Stepha-
nie was born, the Sickle Cell Program, the hospital in 
which Stephanie died, and Stephanie’s pediatrician. 
The physician settled out of court. A jury found the 
Sickle Cell Program negligent in Stephanie’s death 
and awarded damages of $3 million. The Sickle Cell 
Program did not participate in the appeal. The jury 
found that Hutzel Hospital was negligent for failing 
to obtain informed consent for the sickle cell testing, 
but that the negligence was not the proximate cause 
of Stephanie’s death; Hutzel Hospital was thus held 
blameless. The District Court opinion was affirmed on 
appeal.38 In the Dinkins case, the Sickle Cell Program 
that conducted the pilot study was found liable for 
failing to return results because it had a protocol in 
place to return results but was negligent in its failure 
to follow that protocol. It is unclear what the results of 
the litigation would have been if the Sickle Cell Pro-
gram’s protocol had not required that positive results 
be reported. 
These cases demonstrate that the different stake-
holders involved in newborn screening research may 
have different legal responsibilities to the parents 
and infants from whom DBS are obtained depending 
upon the circumstances of the research. Nevertheless, 
there currently is no U.S. case law that establishes a 
legal duty to return results of research conducted 
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using DBS. It is important to note that both of these 
cases involved participation in a pilot program asso-
ciated with new newborn screening tests rather than 
research conducted using de-identified DBS, but the 
significance of this distinction is unclear since the 
court in the Ande case characterized the cystic fibrosis 
study as a research study. 
It is not surprising that there are few reported cases 
that pertain to the return of results from research con-
ducted using DBS, given that much of the research 
conducted using DBS has been conducted using de-
identified samples that have not required parental 
consent. If they never were asked for consent, most 
parents would not know that their child’s DBS had 
been used for research and therefore would not know 
if potentially important results had been withheld 
from them. 
IV. Other Reasons to Return Results from 
Research Conducted Using DBS 
A. The Mandatory Nature of Newborn Screening
In determining whether there are other reasons to 
return results from research using DBS, it is crucial 
to consider the unique context in which these samples 
are collected. Since newborn screening is mandatory 
in most jurisdictions, the DBS used in research would 
not exist but for the state laws that require that they 
be collected. Most states allow parents to opt-out of 
mandatory screening, but few states require that par-
ents be informed of their option to refuse.39 Therefore, 
it is unclear whether the option to refuse screening is 
a real choice. The question then arises whether the 
state’s role in collecting newborn screening samples 
and retaining DBS has any bearing on the decision 
whether to return results to research participants.
State departments of health are responsible for the 
retention and curation of DBS, and state resources 
are used to perform these functions. Although issues 
related to the ownership and control of individual 
samples are not well settled in the law, DBS comprise 
an important public asset that could be extremely 
valuable for biomedical and public health research. 
As guardians of this public asset, state depart-
ments of health have an obligation to be good stew-
ards of these samples. This stewardship entails the 
careful and responsible management of the samples 
that have been entrusted to the care of the state. This 
stewardship also encompasses a duty to act in the best 
interests of those who have entrusted the samples to 
the state newborn screening program. Clearly, learn-
ing research results that could have an impact on the 
health of a child is in the best interests of that child. 
It follows then that a state’s return of research results 
that could be important to the health of the child is 
in the best interests of the research participant and is 
consistent with good stewardship practices.
B. Shifting Views about Whether Research Results 
Should Be Returned
In the past, the prevailing view was that individual 
research results should not be returned to research 
participants. This view has shifted in recent years, and 
although a consensus about which research results 
should be returned remains elusive, there does seem 
to be a consensus that investigators have a limited 
responsibility to disclose certain types of research 
findings.40 The rapid pace of advances in the tech-
nology used in genomic research has further driven 
discussion in this area.41 In the literature, the duty to 
return at least some types of research results has been 
extended to research conducted using archived data 
sets and samples obtained from biobanks.42 Return 
of a limited subset of results from research conducted 
using DBS is consistent with that literature.
C. Increased Utility of DBS Research
Research conducted using DBS has value for two main 
reasons: (1) because samples collected after birth but 
before exposure to environmental factors provide 
information that cannot be obtained at any other time 
of life, and (2) because over time, DBS could provide a 
population-wide database that could be tremendously 
valuable for biomedical and public health research. 
No other types of biospecimens are collected on such 
a large scale.
DBS are the most valuable for research if there is 
high participation, so that the samples are represen-
tative of the population to be studied. The potential 
value of research conducted using DBS will be dimin-
ished if large numbers of parents refuse to allow their 
children’s DBS to be used for secondary research. 
If parental consent is now required to use DBS for 
research, which seems likely given the new federal 
legislation, more parents may refuse to participate. 
Returning research results that may be important for 
the health of their child is one way by which participa-
tion in DBS research can be promoted, since parents 
may be more likely to agree to the use of their child’s 
DBS if they believe that they may potentially learn 
important information about their child’s health. 
However, careful consideration must be given to the 
ethical implications of framing the return of individ-
ual research results as an incentive to allow samples to 
be used, given that the primary goal of research is not 
to benefit individual patients or their families.
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D. Potential Positive Impact on State Newborn 
Screening Programs
It is important to remember that the primary function 
of newborn screening is to identify infants at increased 
risk of disease, not to perform biomedical research. It 
is equally important that any research activities con-
ducted using DBS not jeopardize the public health 
mission of state newborn screening programs. One 
case in which a bad outcome for an infant could have 
been prevented if research results had been returned 
to the infant’s family would be enough to cause a public 
relations nightmare for newborn screening programs. 
In considering whether results of research using DBS 
should be returned to participants’ families, the effect 
of NOT returning results on state newborn screening 
programs should be considered. Whether there is an 
obligation to return a particular result may depend 
upon the severity and treatability of the disease, and 
the obligation may decrease as the potential harm to 
the infant decreases.
Research conducted using DBS has been controver-
sial. The perceived lack of transparency on the part of 
some state departments of health regarding the reten-
tion and use of DBS has been extremely damaging to 
these state newborn screening programs. It is crucial 
that state departments of health maintain public trust 
in newborn screening and the research enterprise. 
Apart from their potential value in other types of bio-
medical and public health research, DBS are a vital 
component in research to improve newborn screen-
ing. It is necessary to preserve states’ abilities to moni-
tor and improve their newborn screening programs. 
Another factor that should be considered is the pos-
itive impact that returning results of research using 
DBS could have on state newborn screening pro-
grams, newborn screening research, and the research 
enterprise. Returning research results could enhance 
community engagement with the research process and 
allow research participants to realize personal ben-
efit from participation in research. In this way, both 
the community and individuals would benefit from 
the research. Returning results also would promote 
transparency regarding the activities of state newborn 
screening programs and their research activities. 
The potential impact of the principle of reciprocity 
also should be considered. In this situation, the state 
newborn screening program would make a promise 
to return research results that may be important for 
the health of the child in exchange for parental per-
mission to release DBS for secondary research. This 
promise could enhance trust in the newborn screening 
program and facilitate cooperation with the research 
enterprise. 
V. If Research Results Are to Be Returned, 
What Results Should Be Returned? 
Although there is a growing consensus that some 
research results should be returned to research par-
ticipants, precisely what results should be returned 
remains debated.43 Advances in genomic sequencing 
technology have further stimulated debate on this 
topic. In considering what results should be returned 
to pediatric patients and their families, discussions 
have centered around issues such as whether to 
return results regarding adult-onset conditions44 and 
whether the guiding standards of the best interests of 
the child should be expanded to include potential ben-
efits to other family members.45 Commentators also 
have considered whether there is a duty to return inci-
dental findings, particularly in the context of pediatric 
genomic research.46 
Although there is a growing consensus that some research results should be 
returned to research participants, precisely what results should be returned 
remains debated. Advances in genomic sequencing technology have further 
stimulated debate on this topic. In considering what results should be returned 
to pediatric patients and their families, discussions have centered around 
issues such as whether to return results regarding adult-onset conditions  and 
whether the guiding standards of the best interests of the child should be 
expanded to include potential benefits to other family members. Commentators 
also have considered whether there is a duty to return incidental findings, 
particularly in the context of pediatric genomic research. 
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This is not the first time that the newborn screen-
ing community has wrestled with the question of 
what results should be returned to infants’ parents. In 
2006, when the ACMG recommended that all states 
adopt a core uniform panel of conditions for newborn 
screening, the ACMG acknowledged that testing for 
those core conditions would also reveal secondary 
conditions that did not meet the criteria for inclusion 
but could be detected in the differential diagnosis of 
core panel conditions. Adoption of the Recommended 
Uniform Screening Panel was encouraged, but it was 
left to individual states to decide whether to report 
any of the secondary findings.47 
For purposes of considering what results of research 
conducted using DBS should be returned, the most 
practical initial approach would be to return only 
actionable results for conditions that would poten-
tially result in an improved clinical outcome for the 
child. This approach would necessitate that effec-
tive treatment or prevention strategies be available. 
In some cases, depending upon the type of research, 
returning aggregate results (for example, to a commu-
nity at risk due to environmental exposures) may be 
more appropriate.
Under an approach that returns results based on 
potential to benefit the child’s health, whether the 
research results are target or incidental findings is 
irrelevant. Of primary importance is whether the 
result has clinical utility. This approach is consistent 
with the purpose of newborn screening, the early 
detection of disease to reduce morbidity or mortality 
for the child. 
When parents are informed that their children’s 
DBS may be used for research, they also should be 
informed that research results that include impor-
tant health information that could potentially result 
in an improved clinical outcome for their child will be 
returned to them. Parents should be informed that if 
they would prefer not to receive research results that 
would potentially benefit their child’s health, they 
should decline to participate in the research. 
If the return of other types of research results, such 
as results that may have clinical utility for other fam-
ily members rather than the child or results related 
to adult-onset conditions, is considered in the future, 
it may be appropriate to allow parents to refuse to 
receive these types of results. However, if the research 
results are deemed to have potential clinical signifi-
cance for the health of the child during childhood, it 
is in the best interests of the child that parents receive 
these results. An approach that would allow parents to 
refuse to receive research results that could benefit the 
health of the child could be damaging to state new-
born screening programs and the research enterprise.
In the future, returning research results that indicate 
risk of an adult-onset disorder and so do not directly 
benefit the health of the child during childhood may 
be considered, but returning these types of results 
should only be undertaken in the context of a research 
protocol to evaluate the effects of providing families 
with this type of information. This type of research 
will be particularly important since little is known 
about the potential harms and benefits of returning 
information about adult-onset disorders and what the 
long-term health and psychosocial effects of returning 
this information might be.48
VI. By What Mechanism Should Research 
Results Be Returned?
If results of research conducted using DBS are to be 
returned to families, there should be a mechanism in 
place by which research results are returned. Using 
the return of positive newborn screening results as a 
model for returning research results is problematic, 
because there is no single mechanism by which posi-
tive newborn screening test results are returned. State 
law and practice vary by state and by condition. 
How results are returned to families and what type 
of follow-up is offered varies depending upon the 
urgency of the condition. The ACMG has published 
ACT sheets for each of the conditions included in 
state newborn screening panels. These ACT sheets 
are intended to provide primary care providers with 
information about the appropriate follow-up and care 
for patients who screen positive for a newborn screen-
ing condition. These ACT sheets recommend differ-
ent courses of action depending upon the condition. 
For example, conditions such as congenital hypothy-
roidism or sickle cell anemia typically are not imme-
diately life-threatening, and consultation with a sub-
specialist with timely confirmatory/diagnostic testing 
as recommended by the specialist are recommended. 
Other conditions, such as galactosemia, can be life-
threatening, and immediate evaluation of the infant 
and referral to a metabolic subspecialist are recom-
mended.49 In addition, there is state-to-state variation 
regarding which party contacts infants’ families for 
follow-up. Whoever receives the positive results bears 
the responsibility to ensure that the infant receives 
the appropriate care. As a result, newborn screening 
represents a complex network of stakeholders whose 
responsibilities vary by state and by condition. Conse-
quently, development of a systematic process by which 
research results can be returned to families presents 
practical challenges. 
 One approach would be to require that all research 
protocols involving the use of DBS have a clear plan 
in place specifying whether and under what circum-
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stances research results will be returned to parents 
and who is responsible for contacting the family and 
informing them of the research results. Clear commu-
nication of results is important to ensure that the ben-
efit of returning results outweighs the potential harms. 
In addition, the research protocol should include suf-
ficient information and procedures to ensure that 
infants with positive research results have access to an 
expert in that particular condition and receive appro-
priate follow-up and care in a timely manner. 
VII. Practical and Ethical Barriers to 
Returning Results of Research Conducted 
with DBS 
Although there may be compelling reasons to consider 
returning a limited set of individual results of research 
conducted using DBS to infants’ parents, doing this in 
practice poses significant practical and ethical chal-
lenges. First, states arguably already are overburdened 
and face challenges maintaining current program 
activities, assuring appropriate and timely follow-up 
with families, and adding new conditions over time to 
their state newborn screening panels.  Asking states 
to be responsible for returning research results will 
undoubtedly place additional burdens on state new-
born screening programs, especially since much of 
the research conducted using DBS will not be con-
ducted by state health departments, but rather by out-
side researchers, with the states then facilitating the 
return of results. One solution could be to require the 
researchers themselves to return research results to 
individuals; however, this requirement would entail 
additional consent requirements and the sharing of 
identifiers with researchers, something many states 
have avoided in order to protect the privacy of fami-
lies.   States are likely to view themselves as stewards 
of DBS, and as an honest broker between researchers 
and families, placing the burden of communicating 
results back on the state programs themselves. 
Second, if research conducted using DBS is car-
ried out on a large scale in the future, the numbers 
of infants whose parents may need to be contacted to 
have results returned may not be trivial.  Communica-
tion of research results to a potentially large number 
of individuals and the provision of ongoing support 
to ensure that they receive adequate follow-up and 
access to treatment may not be practicable in the con-
text of newborn screening programs.  
In some cases, returning aggregate results to sub-
populations or communities may be more feasible 
while at the same time fulfilling an obligation to share 
some kinds of information with families and the pub-
lic. In either case, the associated costs and stress on 
the current newborn screening infrastructure should 
not be overlooked.   If newborn screening programs 
are to be expected to facilitate the return of research 
results, programs will need additional funding and 
resources to accomplish this task. Innovative ways 
to keep track of mobile families, as well as additional 
workforce members whose task it is to locate families, 
may be necessary.  
Given the current political and social concerns 
about the use of DBS, approaching the return of 
results in ways that are sensitive to the expectations 
of parents and the programmatic constraints of the 
newborn screening system is essential. States ulti-
mately are responsible for the development and direc-
tion of their newborn screening practices. It is vital 
that states and other newborn screening stakeholders 
work together to address the potential challenges of 
returning research results and at the same time pro-
tect the public health mission and clinical benefits of 
state newborn screening programs. 
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